Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy Sep 05, 2024 PDF Version FDA approves expanded indication making FILSPARI available to patients with IgA nephropathy (IgAN) at risk of progression; updated label includes data showing long-term…
Read More
Thank you for your interest in accessing our exclusive content. Please note that this section is reserved for ASPN members only. If you're already a member, please log in using your credentials to unlock access using the button below.
If you're not yet a member or if your membership has expired, don't worry! You can easily sign up or renew your membership to gain immediate access to all our valuable resources and benefits.
To sign up or renew your membership, simply click here "Sign Up" or "Renew Membership", and follow the instructions.
Join us for an enriching experience at the 12th Annual ASPN Multidisciplinary Symposium, where professionals from diverse fields come together to advance pediatric nephrology care. This is an essential event for Nurses, Social Workers, Dietitians, Child Life Specialists, Psychologists, and all members of pediatric nephrology teams. Mark Your Calendars: November…
Read More
The ASPN Public Policy Committee has submitted its comments on the proposed NIH reform framework, which was introduced by the House Energy and Commerce Committee. We extend our sincere thanks to the Public Policy Committee for their dedication and advocacy on this critical issue. Their insights and expertise help ensure…
Read More
Travel grants will be awarded on a rolling basis until the designated funds are exhausted. You will receive notification within 2 weeks of submission. Visit the IPNA Congress website for additional details about the meeting and registration. This will be an unparalleled opportunity for trainees to attend the premier international…
Read More
